Associations - RUNX1 mutation

RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials	venetoclax + RO5503781 Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	LY3009120 Resistant: C3 – Early Trials	LY3009120 Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials	cytarabine Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C3 – Early Trials	azacitidine Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials	cytarabine + clofarabine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials	cytarabine + cladribine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials	decitabine + clofarabine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials	decitabine + cladribine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	CDIAG Sensitive: C3 – Early Trials	CDIAG Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Chronic Myeloid Leukemia CML	RUNX1 mutation RUNX1 mutation	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	tagraxofusp Sensitive: D – Preclinical	tagraxofusp Sensitive: D – Preclinical